Dear Friends,

The FARE team is proud to present this Impact Report highlighting the overwhelming successes achieved in 2021. Thanks to the leadership of our Boards, support from our generous donors, and the advocacy of our grassroots communities, we have made tremendous strides towards meeting our goal of securing a future free of food allergies and intolerances, one breakthrough at a time.

We credit our success to best-in-class partnerships formed with leaders in government, business, medicine, and the nonprofit sector. By aligning our programming with organizations that share our goals, and by strengthening our relationships with the National Institutes of Health, the Food and Drug Administration (FDA), and the U.S. Congress, we have maximized the impact of our investments and resources.

We truly are stronger together.

As FARE’s 10th anniversary draws closer, we celebrate the core partnerships that support our 2021 accomplishments. In 2015, FARE created the FARE Clinical Network, which now comprises 51 food allergy centers located in 23 states and the District of Columbia. Collaborations and partnerships within and beyond the Network will help us develop solutions at a faster pace.

Two partnerships announced this year will provide the Network with essential research infrastructure. The FARE Clinical Network Biobank and Biomarker Discovery Center at Cincinnati Children’s Hospital Medical Center will house privacy-protected specimens donated by patients at FARE Clinical Network centers. Linked to privacy-protected electronic health data, these specimens will foster unparalleled opportunities to understand food allergy mechanisms, discover potential treatments, and identify molecular markers for use in diagnosis and monitoring. The FARE Clinical Network Data Coordination Center at Children’s Hospital of Philadelphia will support the design, development, execution, and analysis of research studies, including clinical trials. Data coordination services will assist FARE Clinical Network research teams with protocol development, FDA submissions, and safety oversight.

Our collaborative initiatives are poised to deliver transformational discoveries in food allergy diagnosis and prevention. The first winner(s) of the FARE Innovation Award Diagnostic Challenge (formerly the FAITH Challenge), a competition to bring to market an accessible, affordable, reproducible, patient-friendly diagnostic test, will be announced in the first quarter of 2022. Also supporting diagnostic advances, FARE and Janssen Pharmaceutical Companies of Johnson & Johnson partnered to award a substantial biomarker grant to Dr. Alexandra Santos (King’s College London). Our multi-sectoral approach to prevention through early allergen introduction combines research, education, advocacy, and awareness elements of our SEED (Start Eating Early Diet) study collaboration with Northwestern University and the Ann and Robert H. Lurie Children’s Hospital of Chicago plus conversations involving government and industry to ensure integration of SEED findings into national guidelines and consumer outreach.
Our advocacy efforts in 2021 yielded groundbreaking results. FARE advocates and our food allergy partners helped push the passage of the FASTER Act to require sesame labeling on packaged foods by 2023 and prioritize food allergy research. A Food Allergy Research Caucus built on our partnerships with bipartisan congressional leaders now seeks to pass laws that benefit our families and increase federal funding to help develop new treatments.

Leveraging our partnerships with the Food Allergy Collaborative and FDA, an Externally Led Patient-Focused Drug Development meeting elevated the voices of patients in calling for accelerated discovery, development, and approval of therapeutic products that meet the needs of our community.

To help people navigate food allergies, the FARE Food Allergy Academy learning management system extends our educational offerings to medical clinicians, registered dietitians, and food service professionals, among others. We also continue to invest in enduring initiatives like the College Program, Back to School with Food Allergies, and the Teal Pumpkin Project to increase awareness and provide resources to food allergy patients and their families.

Finally, our work in diversity and inclusion exemplifies the power of partnerships. Equity Equals Excellence: A Blueprint for Access, published this year, is the result of FARE Roundtable meetings that brought together clinical researchers, academics, industry representatives, and food allergy advocates to map a path forward for patient groups to prioritize, address inequities and ensure all members of patient communities are fully represented, especially in the areas of clinical care and clinical research.

Through the FARE Community Access Program, FARE is partnering with South Ward Promise Neighborhood in Newark, NJ, to assess the prevalence of food allergy diagnosis, understand social determinants of health, and identify barriers to research participation and access to care. We also partnered with faith-based organizations such as the Catalyst Missions Group, convening a national advisory council of faith-based leaders to provide critical input into FARE’s efforts to expand its access initiatives to additional communities, such as Washington, D.C., Chicago, and Philadelphia.

I hope you take some time to review this 2021 Impact Report that details our year’s accomplishments. I know you will be as proud as I am of what we have achieved together for the 32 million people with potentially life-threatening food allergies.

Thank you for supporting FARE’s research, education, and advocacy agenda. I have been honored to lead FARE through a period of exponential growth in impact, and I am confident the next decade will build on that growth to attain meaningful prevention and treatment solutions.

Regards,

Lisa Gable
Chief Executive Officer
FARE’S MISSION

We exist to dramatically accelerate cures for food allergies and intolerances by removing barriers and delivering solutions.
FARE 2021:
BY THE NUMBERS

Surpassed $100M committed to our $200M goal

More than 250,000 patients served annually across 51 FARE Clinical Network sites in 23 states and the District of Columbia

A 59% increase in the number of grassroots advocates, to over 70,000

More than 14,000 enrolled in the FARE Patient Registry, with 1,996 added in 2021

Over 41,000 learners joined Food Allergy Academy since its launch last year

The FASTER Act was the 11th bill signed into law during the Biden-Harris Administration’s first 100 days

Digital Engagement Highlights

3.5M page views on foodallergy.org
1.6M unique foodallergy.org visitors

36.8K Followers

+31M social impressions
+960K social engagement
+4M video views

24.2K Followers

200K Followers

5.6K Subscribers
FARE - 2021 Impact Report

MEDIA COVERAGE
Over 10 billion media impressions from January 1 to November 12, 2021

President Signs FASTER Act, Making Sesame Labeling the Law
by Gwen Smith in Food Allergy, News, Soy & Seed
Published: April 23, 2021

The Atlanta Journal-Constitution
Study: 800,000 U.S. adults developed peanut allergy after turning 18
HEALTH | Feb 9, 2021

Changing America
Shared Destiny, Shared Responsibility.
New competition seeks to revolutionize how food allergies are diagnosed
FARE is launching a prize with $3 million in funding.

Newsweek
25 Facts About Food Allergies
BY MISHA GAJEWSKI, STACKER NEWS ON 1/30/21 AT 11:00 AM EST
FOUNDATION FOR RESEARCH:
Expanding the Infrastructure to Accelerate Innovation

FARE has established foundational research platforms that enable clinicians and scientists to collaborate and access critical food allergy-related data to advance research. We are driving innovative clinical trials, fundamental scientific studies, and translational research initiatives to accomplish four key goals:

1. Achieving long-term desensitization to multiple allergens
2. Developing preventative therapies
3. Assessing and monitoring disease activity
4. Understanding disease biology

To tackle these goals, FARE has built a top-tier network of food allergy centers conducting clinical research and patient care within a broader research infrastructure that will enable the development of the unprecedented data resources that are needed to transform food allergy prevention, diagnosis, management, and treatment.
FARE Clinical Network

FARE Clinical Network is a next-generation model for research and patient care, driving collaboration with academic institutions and industry leaders to find real solutions for 32 million Americans with potentially life-threatening food allergies. The Network now comprises 51 food allergy centers located in 23 states and the District of Columbia. In the year since its expansion in 2020, FARE Clinical Network centers have served more than 250,000 patients, of whom 74 percent were under age 18. Collaborations and partnerships within and beyond the Network are helping us develop solutions at a faster pace. Clinical care within the Network is provided by 376 faculty members or private practitioners, 169 fellows, and 184 support staff, including dietitians and psychologists.

More than 45 clinical trials related to food allergy are presently underway at FARE Clinical Network centers. Institutions within the Network are presently engaged in Phase II and Phase III clinical trials with five industry partners to evaluate allergen-based immunotherapies, biologic drugs, or both in combination.
Groundbreaking Studies

**Multi-Allergen Immunotherapy**

Now recruiting children and adults, the **COMBINE trial** will explore multi-allergen oral immunotherapy augmented by two biologic drugs, dupilumab and omalizumab, to attain long-term desensitization of patients to food allergens. Conducted by the Stanford University Sean N. Parker Center for Allergy and Asthma, a FARE Clinical Network Discovery Center of Distinction, with two additional consortium sites, the University of California Los Angeles and University of California San Diego, this trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID) and FARE.

**Food Allergy Prevention**

In the **SEED (Start Eating Early Diet)** initiative for food allergy prevention, FARE is partnering with pediatricians from Northwestern University’s Feinberg School of Medicine and the Ann & Robert H. Lurie Children’s Hospital of Chicago to conduct a comprehensive clinical study. The study is informed by patient insights and designed to evaluate the impact of the early introduction of multiple food allergens to infants. The study will also engage other FARE Clinical Network sites, additional academic institutions, and the FARE Clinical Network Biobank and Biomarker Discovery Center at Cincinnati Children’s Hospital Medical Center. Study data will be employed to support the inclusion of guidance regarding the early introduction of multiple allergens into infant diets in the 2025–2030 U.S. Dietary Guidelines for Americans, influence clinical guideline recommendations by NIAID and the American Academy of Pediatrics, and help shape federal nutrition assistance programs.

**Using Biomarkers to Diagnose and Monitor Food Allergies**

In January 2021, FARE awarded a $500,000 grant to Alexandra Santos, MD, PhD, for her proposal entitled “Clinical Validation of the Basophil and Mast Cell Activation Tests as Food Allergy Biomarkers.” The competitive **Biomarker Research Grant**, co-sponsored by Janssen’s World Without Disease Accelerator, was established to investigate the biology of food allergy and accelerate the development of biomarker-based clinical decision-making tools.
Groundbreaking Studies

Replacing the Oral Food Challenge

This year, to stimulate efforts to identify alternatives to the oral food challenge, FARE launched a $3 million prize, the FARE Innovation Award Diagnostic Challenge (formerly called the FAITH Challenge). The Challenge has resulted in 12 submission packages from both commercial and academic teams around the world. Submissions are currently undergoing a rigorous evaluation by external reviewers and judges, and a winner (or set of winners) will be announced in the first quarter of 2022.

“Our goal is to create an alternative to the oral food challenge that is highly sensitive and specific and has the potential to identify multiple allergens. The optimal assay is easy to use, does not depend on sophisticated instrumentation, and provides clear, reproducible results.” Bruce Roberts, FARE Chief Research Strategy and Innovation Officer.

Exploring Gut Health

In conjunction with Food Allergy Science Initiative (FASI), FARE is in its second year of research in its three-year, multi-million-dollar initiative designed to elucidate the role of the enteric nervous system in food allergy. Ultimately the goal of these efforts will be to generate proof-of-concept data revealing how knocking out targets and/or disrupting pathways can block the cycle of undesirable overreactions to food.

“The interplay of the brain, the gut, and the immune system is largely uncharted territory for researchers. As we map these connections, we expect to find hidden details that no one has anticipated and leads for diagnostics and therapeutics that will ultimately make life safer and simpler for children and adults with food allergies.” Ruslan Medzhitov, director of FASI, principal investigator on the grant, and the Sterling Professor of Immunobiology at the Yale School of Medicine as well as an Investigator with the Howard Hughes Medical Institute.
The past year has witnessed remarkable progress in the development and expansion of game-changing data infrastructure to support food allergy research. To expand the tools available to food allergy researchers, this year FARE has engaged in collaborations with key stakeholders to expand FARE’s registry of food allergy patients, link demographic patient data to biospecimens, and explore methods to extract electronic health record information from FARE Clinical Network sites.

The **FARE Patient Registry** is a secure database through which food-allergic patients and their caregivers share health information with the research community. Enrolling more than 14,000 participants since its 2017 launch, it is the largest registry capturing food allergy disease patterns of U.S. children and adults. In 2021, 1,996 were added to the Registry.
FARE Clinical Network centers help to enroll new participants into the FARE Patient Registry, while the Registry provides Network investigators access to de-identified data stored in the Registry to further their research. Several initiatives are underway to ensure the FARE Patient Registry is representative of the U.S. food allergy population and to facilitate the recruitment of diverse patients into clinical studies. Plans are also in motion to replace the Registry’s legacy technology for collecting patient-reported data with a more robust and scalable alternative.

A collaborative endeavor launched with the research services provider Westat, the FARE Clinical Network Data Coordination Center was established at Children’s Hospital of Philadelphia, a FARE Clinical Network Discovery Center of Distinction. The Data Coordination Center will support critical FARE Clinical Network activities relating to the design, development, execution, monitoring, and analyses of clinical research. Current goals for the Data Coordination Center include developing templates (for example, consent forms) and standard operating procedures, launching a FARE Clinical Network web portal for investigators, analyzing FARE Patient Registry data, and developing a repository for data on the threshold doses of allergen that trigger patient reactions, starting with data from oral food challenges performed at FARE Clinical Network Discovery Centers of Distinction.

The FARE Clinical Network Biobank and Biomarker Discovery Center builds on an existing biobank located at Cincinnati Children’s Hospital Medical Center, a FARE Clinical Network Clinical Research Center of Distinction. FARE Clinical Network researchers, as well as industry partners, will be able to access current and future banked biological samples to support their programs of research.

The Biobank and Biomarker Discovery Center and the Data Coordination Center are collaborating with other FARE Clinical Network institutions to develop a prospective observational study of 1,000 patients/controls that will collect biospecimens for future food allergy research. Network centers will ultimately provide the Biobank and Biomarker Discovery Center with de-identified biological samples linked to clinical data, creating an exceptional tool for food allergy research. Biospecimen samples will also be solicited from individuals enrolled in the FARE Patient Registry.
Within FARE’s innovative research and data infrastructure, FARE Clinical Network centers share reciprocal relationships with the FARE Patient Registry, the Data Coordination Center, and the Biobank and Biomarker Discovery Center. The FARE Clinical Network will serve as a hub for patient recruitment to the Registry and other clinical trials as well as for biospecimen acquisition. Through the FARE Data Commons, these unprecedented overlapping data resources will be made accessible to academic and industry researchers within and outside the Network, supporting discoveries in fundamental and translational research to drive improved outcomes for food allergy patients.
FARE was proud to promote exploration of the latest medical and scientific findings in food allergy at our annual **Contains: Courage® Research Retreat**. Now in its ninth year, the Research Retreat was held online Oct. 18–20. Nearly 50 experts made the event possible by recording presentations, taking part in live question-and-answer sessions, or engaging with their peers in panel discussions. The online format encouraged wide participation and drew more than 400 registrants.
Strengthening Industry Partnerships

The Industry Advisory Council (IAC) was established in 2020 to foster robust, cohesive partnerships with pharmaceutical, biotechnology, and consumer packaged goods industries working across the spectrum of food allergy prevention, diagnosis, and treatment. The mission of the IAC is to provide a collective forum for industries involved in food allergy to align common interests and challenges within the pre-competitive space. The IAC’s core priorities are:

1. Leverage the credibility, expertise, and autonomy of FARE, champion the acceleration of the multi-allergen pathway for approval of new therapies and diagnostics
2. Proactive prevention of food allergy onset by employing strategies to promote immune tolerance induction
3. Amplify the patient voice by enriching our collective understanding of the patient journey and the totality of the disease burden to improve patient care

We have continued to strengthen our engagement with our IAC partners throughout 2021 to explore the three highest priorities articulated by our industry partners.
Research
Publications and Presentations

FARE-supported research resulted in six peer-reviewed manuscripts in leading allergy journals, including *The Journal of Allergy and Clinical Immunology: In Practice*, *Allergy*, and *Annals of Allergy, Asthma & Immunology*. In addition, FARE-supported research was featured in more than a dozen poster abstracts and presentations at national conferences, including AAAAI, the American Academy of Allergy, Asthma & Immunology, and ACAAI, the American College of Allergy, Asthma, & Immunology.
The Food Allergy Safety, Treatment, Education & Research (FASTER) Act

Our advocacy efforts in 2021 yielded groundbreaking results. The more than 70,000 FARE Advocates and our food allergy partners helped push the passage of the FASTER Act to require sesame labeling on packaged foods by 2023 and prioritize food allergy research. In a time of political infighting, the FASTER Act received unanimous approval in the U.S. Senate and was passed by an overwhelming bipartisan majority in the U.S. House of Representatives. The Act was the 11th bill signed into law during the first 100 days of the new Biden-Harris Administration.

Advocating for a Cure

To help push the FASTER Act to passage, 19 cosponsors added their names to the FASTER Act as a result of the 2021 Courage at Congress: Advocate for a Cure Virtual Fly-In, which included more than 500 food allergy advocates (three times more than in 2020) from across the country who participated in 212 congressional meetings.
Establishing the Congressional Food Allergy Research Caucus

The launch of the Congressional Food Allergy Research Caucus in May 2021 built on our partnerships with bipartisan members to pass laws that benefit our families and increase federal funding to help develop new treatments. The Caucus is led by Reps. Doris Matsui (D-CA-06) and Patrick McHenry (R-NC-10) with Reps. Ro Khanna (D-CA-17) and Ben Cline (R-VA-06). The Caucus has now grown to 12 members of the U.S. House of Representatives.

“I’m proud to serve as co-founder and co-chair of the newly formed Congressional Food Allergy Research Caucus, along with Congresswoman Matsui. We recognize there is more we can do to help those 32 million Americans, including many that are children, who suffer from food allergies. We can and we should do more to increase funding into research, therapies, and treatments for food allergies.”

- Representative Patrick McHenry (R-NC-10)

Elevating the Patient Voice

Leveraging our partnerships with the Food Allergy Collaborative and FDA, an Externally Led Patient-Focused Drug Development (EL-PFDD) meeting in September elevated the voices of patients in calling for accelerated discovery, development, and approval of therapeutic products that meet the needs of our community. The PFDD meeting was the first to use a hybrid format, with nearly 50 in-person attendees and nearly 220 additional attendees participating online, including patients; caregivers; friends of those with food allergies; representatives from industry, government, and non-profit organizations; researchers; and healthcare providers.

During the meeting, more than 40 speakers offered valuable patient testimonies and discussed the impact of food allergies on daily life as well as the benefits and burdens of treatment options for food allergies. The FDA received more than 70 written comments during and after the meeting. In addition, over 1,000 patients and caregivers from diverse backgrounds, a sample that represented the national food allergy population, were interviewed and surveyed.
Reducing the Number of Precautionary Allergen Labels (PALs) in Market

Since the development and promotion of FARE’s Food Allergy Consumer Journey in 2020, FARE has worked to reduce the number of precautionary allergen labels (PALs) in the marketplace and align the industry with “May Contain.” To further our efforts, FARE announced a partnership with Label Insight, a NielsenIQ company, which will provide greater transparency to food product information.

Protecting Public School Children through Updating the Child Nutrition Reauthorization (CNR) Act

To protect the nearly 6 million food-allergic children and their families, FARE is encouraging Senate and House lawmakers to include language in the upcoming Child Nutrition Reauthorization (CNR) Act requiring food allergy training for those providing meals to children through the National School Lunch Program (NSLP).
ESTABLISHING EQUITABLE ACCESS AND REPRESENTATION:
A Commitment to Diversity, Equity, Inclusion and Access (DEIA)

Equity Equals Excellence: A Blueprint for Access

Our work in diversity and inclusion exemplifies the power of partnerships. Equity Equals Excellence: A Blueprint for Access, published this year, is the result of FARE roundtable meetings that brought together clinical researchers, academics, industry representatives, and food allergy advocates to map a path forward for patient groups to prioritize, address inequities and ensure all members of patient communities are fully represented, especially in the areas of clinical research and care.
FARE Community Access Program

Through the FARE Community Access Program, FARE is partnering with South Ward Promise Neighborhood in Newark, N.J., to assess the prevalence of food allergy diagnosis, understand social determinants of health, and identify barriers to research participation and access to care. FARE staff presented data from this project at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma, & Immunology (ACAAI) in New Orleans.

We are partnering with faith-based organizations such as the Catalyst Missions Group to convene a national advisory council of faith-based leaders to provide critical input into FARE’s efforts to expand its access initiatives to additional communities, such as Washington, D.C., Chicago, and Philadelphia.

Representation in Food Allergy Research

Several initiatives are underway to ensure the FARE Patient Registry is representative of the U.S. food allergy population and to facilitate the recruitment of diverse patients into clinical studies. For example, Patient Registry Diversity Grants were awarded at six sites to hire research coordinators dedicated to the recruitment of racially and culturally diverse patient populations to the Registry. In addition, FARE has engaged Community Advisors on Research Design and Strategy (CARDS) to improve the readability, comprehension, and reach of marketing collateral used to promote the Registry. FARE has also engaged Recruitment, Inclusion, Service, and Engagement of Underrepresented Populations (RISE-UP) to publish a set of guidelines that illuminate the most sustainable path to promoting Black participation and retention in food allergy patient registries.

Community Access Award

The Patient-Centered Outcomes Research Institute (PCORI) approved a $249,663, two-year award to FARE for work in Washington, D.C., that will enable Black food allergy patients from low-income, systematically disenfranchised Wards 7 & 8 to participate in patient-centered and comparative effectiveness research. The project will build a local Advisory Council of community stakeholders that will include local collaborators from Children’s National Hospital, Catalyst Missions Group, Health Alliance Network, and AllergyStrong.

Start Eating Early Diet (SEED) Study

As part of the Start Eating Early Diet (SEED) initiative, a multi-site clinical study will recruit 1,800 infants from Chicago, which is ranked 10th among the nation’s most diverse cities.
Partnering with the Miami Dolphins

In 2021, the Miami Dolphins and FARE announced a partnership designed to raise food allergy awareness and provide Dolphins fans and the South Florida community with equitable access to options free from the Top 8 food allergens. This will be the first FARECheck® sports partnership, and Hard Rock Stadium is the first venue to create a special kitchen designed to produce allergy-friendly concession offerings.
Living Teal

We also continue to invest in enduring initiatives to increase awareness and provide resources to food allergy patients and their families. During Food Allergy Awareness Week, FARE turned the Empire State Building teal, helped community members solicit official proclamations in 36 states and the District of Colombia, fueled the spike in hashtag traffic for #FoodAllergy, #FoodAllergyAwareness, and #TealTakeover to an impressive 79.2M impressions over the week, and drove 387,000 views and 1,250 hours of content watched.

FARE continues to be recognized as best-in-class by our peers in marketing and media circles. Living Teal programs received seven Telly Awards for excellence in video content (including Best in Category for “Around the World in 80 Plates” at the New Media Film Festival), four Hermes Awards recognizing Living Teal content, and a Gold MUSE Creative Award for the most innovative social media campaign for our collaboration with Yum Earth.

In addition, we achieved these results on our social platforms for other key campaigns during the year:

- Easter promotion: 2.2M impressions, 44K engagements
- Back to School: 8.9M impressions, 165K engagements
- Teal Pumpkin Project: 91.2M impressions, 236.7K engagements

FARE’s 2021 Bite-sized Snacks campaign for Top 9 lunchtime snacks.
Informing Caregivers and Stakeholders with Educational Webinars

In 2021, FARE provided 17 free educational webinars featuring leading subject-matter experts who provided technical information, practical knowledge, advice, and quality resources for families, caregivers, and stakeholders impacted by food allergy. Over 70% of webinars were approved for continuing education credits by the Commission on Dietetic Registration (CDR). Each webinar brought in an average of 200 new contacts into FARE’s database, and over 31,500 individuals engaged in FARE’s webinar series this year.

Support Groups and Support Group Leaders Connecting with Patients at the Local Level

In 2021, FARE expanded leadership and patient engagement opportunities for support group leaders and their members by leveraging their expertise, matching them with external partners, and providing them with the opportunity to help inform the development of food therapeutics and diagnostics. For example:

- More than 40 support group leaders and members completed FARE’s surveys to share insights about products, services, and unmet needs for the benefit of the food allergy community.
- Five support group leaders participated in a 3-hour roundtable session to discuss patient perceptions of the benefits and barriers of oral immunotherapy (OIT), providing Aimmune Therapeutics with ground-level feedback on what resources and information Aimmune should include in shared decision-making tools for parents and caregivers considering OIT as a treatment option.
- Nearly 10 support group leaders participated in two, 1-hour roundtable sessions to discuss the assumed efficacy and feasibility of the peanut patch, providing specific feedback to DBV Technologies relating to patch adhesion.

Supporting Local Communities

In 2021, FARE awarded more than $47,000 in Community Outreach Awards to fund 14 projects that served communities across 14 states. These projects focused on increasing access to food allergy care and resources in underserved communities in partnership with local schools, allergists, libraries, mental health practitioners, food assistance programs, and more.

FARE also awarded approximately $9,000 in stipend awards to 19 FARE-Recognized Support Groups serving food allergy families across 12 states to ensure those within the food allergy community stay connected, informed, and supported.
FARE Collaborators Program and Collaborator Community Impact Awards

The FARE Collaborator Program promotes food allergy awareness where people work, play, live, and study by working with community organizations, educational institutions, and government agencies that care about the issue. This year FARE awarded nine grants totaling $6,800 to schools or community organizations serving more than 21,000 students attending Title I or Title I-eligible schools to support food allergy education and awareness. Awardees used the funding to acquire food allergy-friendly foods for school food pantries, acquire educational materials, and provide training to school staff.

Girl Scout Partnership

In 2021, 13 new Girl Scout Councils joined the Food Allergy Awareness Patch Program. The program now reaches 464,000 scouts and volunteers in 19 Councils across the country, most serving underserved urban or rural communities.

Engaging Children and Teens with Food Allergies

FARE hosted monthly Child Chats (20 children per chat) and Teen Talks (40–80 teens per talk). This year, 242 teens in the Teen Advisory Group (TAG) participated and contributed to dozens of blogs, social media posts, and volunteer projects ranging from food drives in their communities to social media awareness campaigns.

Providing Access to Training and Resources

FARE’s learning management system delivers online courses, interactive training, and educational content. The FARE Food Allergy Academy, FARE’s learning management system, delivers educational content for the food allergy community and professionals that support them like healthcare providers, registered dietitians, and food service professionals. In the first full year of our learning-management system course delivery, over 41,000 individuals have taken FARE Food Allergy Academy courses.

Pediatric Food Allergy Course

The Pediatric Food Allergy Course was one of the first professional education courses to launch on FARE Food Allergy Academy. The 9-month online program prepares healthcare and service providers to support food allergy families by offering evidence-based care and nutrition counseling for pediatric patients within and outside the U.S. In 2021, we added a third class to the course, which increased enrollment from 40 last year to 68. Through this course, we are reaching dietitians, pediatricians, and nurses who work in a variety of settings, from clinics to schools to WIC offices. In addition, six class participants working with underserved populations were awarded full or partial scholarships to support better access to quality care for the food allergy community. FARE’s reach into the international community included learners from Romania, Saudi Arabia, Mexico, Canada, South Africa, and China.
FARECheck® Training and Certification for Professionals

FARECheck® partners with workers and establishments to standardize training and help build a staff that is knowledgeable about and confident in safe food handling. To date, nearly 13,000 food service workers have completed a FARECheck® course. In 2021, FARECheck® announced a new, three-tiered program:

- **FARECheck® Trained**: Awarded when an individual staff member has completed on-demand or instructor-led training provided by FARE or a third-party allergen training program reviewed and certified by FARE.
- **FARECheck® Silver**: Awarded when at least 90% of a food establishment’s workforce has been trained in food allergy safety.
- **FARECheck® Gold**: Awarded when, in addition to achieving FARECheck® Silver status, food establishments also undergo a food service policy review and an annual onsite visit. In 2021, FARE piloted the FARECheck® Gold program with three Sodexo-operated dining services at colleges and universities and the Miami Dolphins’ Hard Rock Stadium.

FARE College Food Allergy Program

FARE launched the College Food Allergy Program in January 2014 to improve safety and quality of life for college students with food allergies. FARE’s Food Allergy College Search is a database that allows prospective students to search colleges and universities by their food allergy accommodations including dining options, housing accommodations, emergency services, and more. FARE’s Food Allergy College Search has grown to include 1,093 colleges and universities.

FARE College Food Service Summit

FARE hosted its 3rd annual College Summit, which brought together 271 registrants representing hundreds of universities. This event included three days of educational content, 16 speakers, and six exhibitors, and received highly positive post-program evaluations from 97% of the participants. Individuals who participated in the post-program survey represented over 5,000 dining locations. Award recipients include:

- **Best Campus Dining Award**: Tufts University
- **Community Choice Award**: Bowling Green State University
- **Honorable Mention, Best Campus Dining Award**: Moravian University
- **Honorable Mention, Community Choice Award**: James Madison University
BOARD ROSTERS

Board of Directors
David Jaffe  David G. Bunning  Helen Jaffe  Mary Weiser
Chair  Director  Member at Large  Director
Alan Hartman  Leigh Feuerstein  Adam Miller  Member at Large
Vice Chair  Director  Director  
Milton Brown, MD  Dev Ganesan  Robert L. Rich  Director
Director  Director  Director  

Board of Governors
Denise A. Bunning  David A. Crown, Ph.D.  Rebecca Lainovic  Robert Nichols
Co-Chair  Co-Chair  BOD 2016-2021  
Kim Hartman  Talia and Andrew Day  Julie and Paul Leff  Christine Olsen, MD
Co-Chair  MD  MD  
Janet Atwater  Rachel J. Gordon, MD, MPH  Don Levin  Cari and Michael J. Sacks
Hillary and Ben Carter  John J. Hannan  Louise Matthews, MD  Sara Trachte

Board of National Ambassadors
Kaye W. Cole, Ph.D.  Andrew Gilman  Michael Lade  Katie Rogers
Co-Chair  
Kimberly Yates  Antoinette and Michael Griffith  Sharon Lamberton, MS, RN  Melissa and Matt Rubel
Co-Chair  
Jenny Andjelkovic  Priscilla Hernandez  Wende Fox Lawson  Debbie Spano
Alisa Brodkowitz  Julie Karish  Shelby and Steve Lewis  Lori Stokes
Jeffrey Burman  Stacy Klein  Alison Marquiss  Karin Teglia
Tara and Josh Geise  Sara Krahenbuhl  Noreen Okarter  Julie Wilcox
Co-Chair  
Rising Leaders Committee
Daniel Kadden  Lauren Byrne  Jack Griffith  Alexa Moss
Co-Chair  
Carlo Steinman  Jamie Carnavalla  Carly Klein  Joy Reines
Co-Chair  
Sarah Ackerman  Kendra Chapman  Katie Klein  Jake Shirian
Bryan Bunning  Dana Friedman  Matthew Marangiello  Lauren Soltwisch

OUR DONORS

$5M+
Christine Olsen, MD and Robert Small
Sunshine Charitable Foundation – Denise and Dave Bunning

$2.5M-$4.9M
Anonymous
Hartman Family Foundation

$1M-$2.4M
1P Foundation
Anna-Maria and Stephen Kellen Foundation
Laura and Jonathan Beinner
Helen and David Jaffe, and the Jaffe Family
Anna and Peter Kolchinsky
Naddisy Foundation, Inc.
Ira and Diana Riklis Family
The Weiser Family

$250,000-$499,999
The Donald Levin Family Foundation
Cari and Michael J. Sacks

$100,000-$249,999
Anonymous
Hillary and Ben Carter
DBV Technologies, Inc.
Rachel and Tim Gordon
John J. and Judith Hannan
Julie and Paul Leff
Dr. Louise Matthews and Thomas Flickinger
(Edward E. and Marie L. Matthews Foundation)
OWYN
Thermo Fisher Scientific

$50,000-$99,999
Aimmune Therapeutics
Applegate Farms
Wende Fox Lawson and Jim Lawson
Linda and Bill Friend and The Harris Family Foundation
Gayden Foundation
Laura and Dan Gold
Hankin Family Charitable Fund
Jacqueline R. Fern Trust
Reckitt / Mead Johnson Nutrition
The Safe + Fair Food Company
Ravi Singh and WearSafe
Trachte Family Foundation

$10,000-$49,999
Anonymous
AmazonSmile Foundation
Dr. Sharman and David Altshuler
Amir and Rosita Manocherian Family Foundation

Jenny Andjelkovic
Janet and Peter Atwater
Amy and Keith Barnett
Jamie and David Baron
Boyle Family Foundation
Compass Group
Daiya Foods Inc.
Danone/Nutricia North America
Rachael and Robert Dedman
Chelsea and Marty Dorchich
Lisa and Jim Gable
Tara and Josh Geise
Jonathan and Adena Goldberg
Antoinette and Michael Griffith
Hittman Family Foundation
Mary Holloway
Christine and Timothy Johnson
Kaleo, Inc.
The Karin and Dean Teglia Family Foundation
Stacy and Ron Klein
Mary Kriauciuunas
Steve and Shelby Lewis
Ellen Liu
Barbara Manocherian
Kristine and David Meyer
Vicki and Dillard Jeffrey Moore
Rebecca and Robert Nichols
Novartis
Perfect Day
Peter R. Schneider Family Foundation
PhRMA
Robert L. Rich
Cara Rooney Moore
Melissa and Matthew Rubel
Sandhya and Naresh Sabhnani
Debbie Spano
Tepas Family Foundation
Cristina and Matt Wallach
Jaimie S. Yeh

$5,000-$9,999
ACAAI
Robin and Philippe Amouyal
API Restauration
ARS Pharma
Auth Family Charity
Sophie Bacher
Brickbottom Foundation
C.A. Shea and Company, Inc.
Kathryn and James Caissy
Campbell Family Foundation
Phillip and Mary Beth Canfield
Capital Group Co Charitable Foundation
Carolyn W. and Charles T Beaird Family Foundation
Royal and Elizabeth Caswell
James and Mariah Collins
David and Haitran Coulter
Deseret Trust Company
Niall Devitt
Deyo Family Charitable Fund
Doris and Stanley Tananbaum Foundation
Chris and Deb Doughty
Draydor Foundation
David and Cory Drewes
East Rock Capital
Douglas Fainelli
Feldstein Family Charitable Foundation
Darrel and Sandy Fry
Manindra Garg
Gale Gero
Pooja Goradia
H.L. Epstein Family Foundation, Inc.
Kristi Hoffman
Jane Julius and Julie Karish
LA-CO Industries
Leslie C. and Leonard A. Shapiro Family Foundation
Serena Liew
Richard Lowenthal
Luca + Danni
Luxor Capital Group
Jill and Paul Meister
Joseph and Katherine Mele
Merkel Foundation
Milton’s Craft Bakers
Natter Family Foundation
Eric Piesner
Robert Rizzuto
Katie and Ken Rogers
Sheli and Burt Rosenberg
Leah and Scott Rued
Vivian F. Sangunett
Shapiro/Schwartz Family Fund
Shenandoah Swim Club
Singer Family Foundation
Linda Sink
Timothy Sprangers
White Mountains Capital, LLC
Mike and Rita Wilson
Wintrust Financial
VG Growth Partners
Cynthia Zanzig and Perry Gore

$2,500-$4,999

Apple Matching Gifts Program
Aimee and Michael Benz
Jeffrey and Cheryl Burman
Julie, Brian and Chad Burrow
Butlein Family Foundation
Chubb Charitable Foundation
Christine Creter
Kathleen Crockett
Dell Technologies
Katherine Eitel
Every Body Eat (Whole and Free)
George and Judith Arangio Foundation Trust
Andrew Gilman
David and Patricia Grayson
Katie Greenberg
Jodi Gruber
Hamilton Executions
Harbor Seafood Inc.
Hercules Capital
Christopher and Maureen Hurst
JP Morgan Chase Foundation
Brooke and Peter Jepsen
Jerome J. and Ursula Choromanski Family Foundation
John and Rita Lowndes Family Fund
Liberty Mutual Employee Giving
Brooke MacLean
MacMahon Family Charitable Fund
Maine Community Foundation
Shonna Mayfield
Nicholas Melone
Jeff Meyers
Microsoft Employee Giving
Amy Mijas
Moss Family Trust
NFL Foundation
Steven Onishi and Dawn Alling
PepsiCo Employee Engagement Fund
Kraig Peterson
RCP Foods, LLC
Joan and Steven Risavy
Sifter
Heather Staples
Shelby Staples
Stephen Colbert Americone Dream Fund
Cynthia Waite
Gilbert Wootton
Annabel Wrightsman
Timothy and Kathy Yerdon

THANK YOU!
As a leading non-governmental organization, FARE is committed to maintaining the utmost accountability and transparency to the people that we represent, the general public, our donors, and our corporate partners. Our goal is to ensure that every dollar donated to FARE is spent meticulously and efficiently. For purposes of financial transparency, FARE includes the most recently audited financial information in our Impact Report. Therefore, the financial data will typically lag the rest of the Impact Report by one calendar year.

2020 was the year FARE fully engaged in executing our Five-Year Plan while adapting to the impact of COVID-19 on our operations and partners. We learned to embrace virtual events for our Contains: Courage® Research Retreat and Living Teal Global Summit and moved our scheduled in-person Global Summit to 2022. Our Creative Services team launched the Living Teal Channel to provide entertaining educational resources for the community. Inside our financial picture, our spending for donor, sponsor, and community events shifted from in-person to virtual interactions starting on March 16, 2020.

FARE raised $18.9 million in 2020. Around 71% of total support and contributions came from our major donors and 18% from corporate and foundation sponsorships. Over the period 2017 to 2020, revenue in 2020 surpassed all but the record level set in 2019. In 2019, we expanded the FARE Clinical Network and began construction of the FARE Data Commons as a resource for clinical trials and studies specific to food allergy. We believe our strategic fundraising capabilities remain strong as we look to develop additional funding from industry, foundations, and data-related services. Revenue results for 2020 were unquestionably impacted by the year’s external events, along with our inability to have necessary face-to-face meetings with existing and new donors.
Our total spending in 2020 was $21.5 million, an increase of $8.5 million driven principally by our year-to-year increase in research grants spending of $7.2 million. Consistent with our strategy to emphasize Research, we spent 83% of total expense on program and mission-centric research, education, and advocacy expenses in 2020, compared to 72% in 2019. At the same time, we were able to reduce the spending on supporting services by 10% compared to 2019. General management expenses were to 8% in 2020, and fundraising expenses were 9%.

FARE’s balance sheet remained strong, with total cash and cash equivalents of $21 million on hand at the end of 2020 compared to $17 million at year-end 2019. The cash and cash equivalents at year-end 2020 represented approximately 12 months of anticipated expenses in 2021. Adding to that operating asset base was $6.5 million of pledge receivables at year-end 2020. Strategic cash assets were contained in the $33 million endowment cash balance on December 31, 2020, of which approximately $21 million was Board-directed to support strategic research and program initiatives in 2021 and subsequent years.

The financial data highlighted here are derived from our audited financial statements. A complete set of those financial statements can be obtained on our website at www.foodallergy.org.

### Financial Highlights

<table>
<thead>
<tr>
<th>Selected balance sheet data (at the end of the year)</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$18,951,427</td>
<td>$17,104,120</td>
</tr>
<tr>
<td>Investments</td>
<td>34,972,668</td>
<td>40,146,459</td>
</tr>
<tr>
<td>Pledges receivable, net</td>
<td>7,651,599</td>
<td>7,747,034</td>
</tr>
<tr>
<td>Total assets</td>
<td>61,884,454</td>
<td>65,608,655</td>
</tr>
<tr>
<td>Accounts payable including grants payable</td>
<td>1,770,229</td>
<td>2,527,853</td>
</tr>
<tr>
<td>Net assets without donor restrictions</td>
<td>43,755,090</td>
<td>48,839,874</td>
</tr>
<tr>
<td>Net assets restricted by donors for purpose or time</td>
<td>16,086,862</td>
<td>13,877,581</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selected statement of activities revenue data</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contribution revenue from major donors</td>
<td>$13,452,715</td>
<td>$15,475,960</td>
</tr>
<tr>
<td>Support from the general public</td>
<td>1,251,805</td>
<td>1,401,418</td>
</tr>
<tr>
<td>Corporate and foundation sponsorships</td>
<td>3,430,910</td>
<td>4,649,362</td>
</tr>
<tr>
<td>Special events</td>
<td>316,501</td>
<td>1,005,591</td>
</tr>
<tr>
<td>Other income</td>
<td>504,554</td>
<td>82,890</td>
</tr>
<tr>
<td>Total operating revenue</td>
<td>18,956,485</td>
<td>22,615,221</td>
</tr>
<tr>
<td>Net investment income (loss)</td>
<td>(250,850)</td>
<td>929,605</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Data from the statement of functional expense</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research and clinical studies</td>
<td>$11,321,967</td>
<td>$3,925,030</td>
</tr>
<tr>
<td>Education and advocacy</td>
<td>3,647,770</td>
<td>3,260,960</td>
</tr>
<tr>
<td>Awareness and community outreach</td>
<td>2,948,599</td>
<td>2,282,991</td>
</tr>
<tr>
<td>Fundraising</td>
<td>1,875,321</td>
<td>2,105,707</td>
</tr>
<tr>
<td>General and administrative</td>
<td>1,745,313</td>
<td>1,478,588</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>21,538,970</td>
<td>13,053,276</td>
</tr>
</tbody>
</table>

| Headcount                                           | 51         | 36         |